vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and Cardlytics, Inc. (CDLX). Click either name above to swap in a different company.

Cardlytics, Inc. is the larger business by last-quarter revenue ($50.9M vs $48.0M, roughly 1.1× BICYCLE THERAPEUTICS PLC). On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -25.5%). Cardlytics, Inc. produced more free cash flow last quarter ($13.0M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs -9.6%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Cardlytics is a leading purchase intelligence and advertising platform that partners with major banks to analyze anonymized consumer transaction data. It delivers targeted, performance-driven ad campaigns for consumer brands, retailers and service providers, helping advertisers reach audiences based on real purchase behavior, with core operations across North America and the United Kingdom.

BCYC vs CDLX — Head-to-Head

Bigger by revenue
CDLX
CDLX
1.1× larger
CDLX
$50.9M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1218.7% gap
BCYC
1193.3%
-25.5%
CDLX
More free cash flow
CDLX
CDLX
$32.9M more FCF
CDLX
$13.0M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
-9.6%
CDLX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCYC
BCYC
CDLX
CDLX
Revenue
$48.0M
$50.9M
Net Profit
$-20.2M
Gross Margin
Operating Margin
-51.5%
-12.0%
Net Margin
-42.0%
Revenue YoY
1193.3%
-25.5%
Net Profit YoY
61.1%
EPS (diluted)
$-0.29
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
CDLX
CDLX
Q4 25
$48.0M
$50.9M
Q3 25
$11.7M
$47.0M
Q2 25
$2.9M
$58.0M
Q1 25
$10.0M
$56.4M
Q4 24
$3.7M
$68.3M
Q3 24
$2.7M
$61.1M
Q2 24
$9.4M
$64.0M
Q1 24
$19.5M
$62.2M
Net Profit
BCYC
BCYC
CDLX
CDLX
Q4 25
$-20.2M
Q3 25
$-59.1M
$-72.7M
Q2 25
$-79.0M
$-9.3M
Q1 25
$-60.8M
$-13.3M
Q4 24
Q3 24
$-50.8M
$-145.2M
Q2 24
$-39.8M
$-4.3M
Q1 24
$-26.6M
$-24.3M
Operating Margin
BCYC
BCYC
CDLX
CDLX
Q4 25
-51.5%
-12.0%
Q3 25
-558.6%
-146.6%
Q2 25
-2965.8%
-22.0%
Q1 25
-703.7%
-24.9%
Q4 24
-12.2%
Q3 24
-2385.9%
-243.1%
Q2 24
-498.3%
-24.7%
Q1 24
-162.4%
-36.7%
Net Margin
BCYC
BCYC
CDLX
CDLX
Q4 25
-42.0%
Q3 25
-503.7%
-154.7%
Q2 25
-2703.8%
-16.0%
Q1 25
-608.9%
-23.5%
Q4 24
Q3 24
-1898.4%
-237.6%
Q2 24
-425.3%
-6.7%
Q1 24
-136.0%
-39.0%
EPS (diluted)
BCYC
BCYC
CDLX
CDLX
Q4 25
$-0.29
$-0.15
Q3 25
$-0.85
$-1.36
Q2 25
$-1.14
$-0.18
Q1 25
$-0.88
$-0.26
Q4 24
$-0.36
Q3 24
$-0.74
$-2.90
Q2 24
$-0.77
$-0.09
Q1 24
$-0.62
$-0.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
CDLX
CDLX
Cash + ST InvestmentsLiquidity on hand
$628.1M
$48.7M
Total DebtLower is stronger
$212.6M
Stockholders' EquityBook value
$610.0M
$-6.5M
Total Assets
$717.6M
$285.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
CDLX
CDLX
Q4 25
$628.1M
$48.7M
Q3 25
$648.3M
$44.0M
Q2 25
$721.5M
$46.7M
Q1 25
$793.0M
$52.0M
Q4 24
$879.5M
$65.6M
Q3 24
$890.9M
$67.0M
Q2 24
$961.4M
$71.2M
Q1 24
$457.0M
$97.8M
Total Debt
BCYC
BCYC
CDLX
CDLX
Q4 25
$212.6M
Q3 25
$214.6M
Q2 25
$214.3M
Q1 25
$213.9M
Q4 24
$213.6M
Q3 24
$213.2M
Q2 24
$30.9M
$212.9M
Q1 24
$30.8M
$257.9M
Stockholders' Equity
BCYC
BCYC
CDLX
CDLX
Q4 25
$610.0M
$-6.5M
Q3 25
$618.5M
$-4.7M
Q2 25
$668.9M
$58.7M
Q1 25
$740.3M
$64.1M
Q4 24
$793.1M
$70.0M
Q3 24
$831.0M
$69.7M
Q2 24
$873.8M
$210.0M
Q1 24
$356.0M
$199.1M
Total Assets
BCYC
BCYC
CDLX
CDLX
Q4 25
$717.6M
$285.6M
Q3 25
$764.0M
$292.8M
Q2 25
$832.2M
$361.1M
Q1 25
$883.9M
$369.1M
Q4 24
$956.9M
$392.7M
Q3 24
$996.7M
$399.4M
Q2 24
$1.1B
$534.4M
Q1 24
$547.1M
$569.0M
Debt / Equity
BCYC
BCYC
CDLX
CDLX
Q4 25
Q3 25
Q2 25
3.65×
Q1 25
3.34×
Q4 24
3.05×
Q3 24
3.06×
Q2 24
0.04×
1.01×
Q1 24
0.09×
1.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
CDLX
CDLX
Operating Cash FlowLast quarter
$-19.3M
$13.0M
Free Cash FlowOCF − Capex
$-19.9M
$13.0M
FCF MarginFCF / Revenue
-41.5%
25.5%
Capex IntensityCapex / Revenue
1.2%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
CDLX
CDLX
Q4 25
$-19.3M
$13.0M
Q3 25
$-71.2M
$1.8M
Q2 25
$-72.8M
$1.2M
Q1 25
$-86.4M
$-6.7M
Q4 24
$-164.7M
$3.0M
Q3 24
$-39.8M
$1.4M
Q2 24
$-44.6M
$4.4M
Q1 24
$-70.9M
$-17.6M
Free Cash Flow
BCYC
BCYC
CDLX
CDLX
Q4 25
$-19.9M
$13.0M
Q3 25
$-71.8M
$1.7M
Q2 25
$-73.3M
$903.0K
Q1 25
$-87.0M
$-6.8M
Q4 24
$-166.0M
$2.9M
Q3 24
$-40.3M
$878.0K
Q2 24
$-45.0M
$4.1M
Q1 24
$-70.9M
$-18.3M
FCF Margin
BCYC
BCYC
CDLX
CDLX
Q4 25
-41.5%
25.5%
Q3 25
-612.3%
3.7%
Q2 25
-2509.7%
1.6%
Q1 25
-871.7%
-12.1%
Q4 24
-4475.7%
4.2%
Q3 24
-1504.7%
1.4%
Q2 24
-481.2%
6.5%
Q1 24
-362.9%
-29.4%
Capex Intensity
BCYC
BCYC
CDLX
CDLX
Q4 25
1.2%
0.0%
Q3 25
5.7%
0.0%
Q2 25
17.1%
0.6%
Q1 25
6.1%
0.2%
Q4 24
33.3%
0.2%
Q3 24
16.3%
0.8%
Q2 24
4.5%
0.4%
Q1 24
0.1%
1.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons